Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT07850336

Pancreatic Endoscopic Ultrasound-guided RadioFrequency for Inoperable Carcinoma Treatment

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC)

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 56
Sponsor: Bojan Kovacevic

Summary

The purpose of this study is to evaluate whether endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) affects survival in patients with inoperable pancreatic carcinoma. By using a prospective single-arm design with historical controls, this study aims to generate clinically relevant data while minimizing the number of patients exposed to experimental treatment. The findings may support future integration of EUS-RFA into standard care for this high-need patient population.

Eligibility Criteria

Inclusion Criteria: * Adult habile patients with a signed informed consent * Histologically confirmed pancreatic carcinoma ≤5 cm in largest diameter * ECOG performance status 0-2 * Patients not eligible for curative-intended surgical treatment due to: Advanced (unresectable) disease, or Unsuitability for surgery due to comorbidities or poor performance status, or Patient preference to decline surgery Exclusion Criteria: * Metastatic disease * Uncorrected coagulopathy (INR ≥1.5 or thrombocyte count \< 50 mia/L) * Altered anatomy or interposition of major vessels precluding safe EUS-RFA * Active untreated infection or pancreatitis * Life expectancy \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07850336). StuddyBuddy aggregates publicly available trial information.